<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01536002</url>
  </required_header>
  <id_info>
    <org_study_id>1.2007.366</org_study_id>
    <nct_id>NCT01536002</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics of Propofol in Morbidly Obese Patients</brief_title>
  <official_title>Pharmacokinetics (PK) of Propofol in Bariatric (Morbidly Obese) Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oslo University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of this study are

        -  To determine PK of propofol in bariatric patients

        -  To identify the physiological variables that induce propofol PK changes in bariatric
           patients, when compared to a normal-weight population.

        -  To define context-sensitive half-time profiles for propofol in bariatric patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 7, 2011</start_date>
  <completion_date type="Actual">May 7, 2014</completion_date>
  <primary_completion_date type="Actual">May 7, 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Propofol plasma concentrations</measure>
    <time_frame>0-24 hours</time_frame>
    <description>Arterial blood samples will be collected 0, 1, 2, 4, 8, 10, 15, 20, 25, 30, 45, 60, 75, 90, 120, 150, 180, 210, 240, 300, 360, 480, 600, 720, and 1440 min after start of propofol bolus infusion. 2 samples will be collected at 0 and 1440 minutes, respectively. The remaining 6 blood samples will be collected according to a block sampling regimen, selected randomly within a time block containing 4 consecutive time points from the time point list noted above. In total 8 samples are drawn from each patient.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">69</enrollment>
  <condition>Obesity, Morbid</condition>
  <arm_group>
    <arm_group_label>Pharmacokinetics</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Propofol pharmacokinetics</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propofol</intervention_name>
    <description>Intravenous infusion over 30 min of Propofol 3-4 mg/kg body weight</description>
    <arm_group_label>Pharmacokinetics</arm_group_label>
    <other_name>Diprivan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Consecutive patients admitted to the Aker University Hospital, scheduled for general
             or bariatric surgery,

          -  Both genders. Female subjects of childbearing potential must be using adequate
             contraception (i.e. using oral or IM contraception or an IUCD) and must have a
             negative pregnancy test (urine beta-HCG).

          -  Aged 18 - 60 years, both inclusive

          -  Body mass index (BMI) â‰¥ 20 kg/m2

          -  Written informed consent

        Exclusion Criteria:

          -  Patients that are considered not to tolerate a standard dose of propofol administered
             as a bolus.

          -  Known hypersensitivity to propofol or its ingredients (soy, lecithin, glycerol, oil
             acid)

          -  Known hypersensitivity to any of the anesthetic agents to be used

          -  Pregnant women

          -  Lactating women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tom Heier, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oslo University Hospital, Oslo, Norway</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Oslo University Hospital</name>
      <address>
        <city>Oslo</city>
        <zip>0514</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 10, 2012</study_first_submitted>
  <study_first_submitted_qc>February 15, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 20, 2012</study_first_posted>
  <last_update_submitted>May 26, 2017</last_update_submitted>
  <last_update_submitted_qc>May 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oslo University Hospital</investigator_affiliation>
    <investigator_full_name>Tom Heier</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Bariatric surgery</keyword>
  <keyword>Anesthetics, intravenous</keyword>
  <keyword>Propofol</keyword>
  <keyword>Pharmacokinetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity, Morbid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propofol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

